Vanguard Global Advisers
BTAI icon

Vanguard Global Advisers’s BioXcel Therapeutics BTAI Stock Holding History

Vanguard Global Advisers’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$695 Hold
493
– – ﹤0.01% 3627
2026
Q1 		$661 Buy
+493
New +$812 ﹤0.01% 3651

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
P
&Partners Nashville, Tennessee $24.4B AUM 27.45% 1-Year Est. Return

Vanguard Global Advisers's BTAI Position: Q2 2026 in Review

Vanguard Global Advisers held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 493 shares worth $695. The position accounts for ﹤0.01% of the portfolio, ranked #3627.

Vanguard Global Advisers first reported a position in BTAI in Q1 2026 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Vanguard Global Advisers held 493 shares of BioXcel Therapeutics worth $695 as of Q2 2026.
  • Vanguard Global Advisers left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3627 holding.
  • Vanguard Global Advisers first reported a position in BioXcel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.